AMARIN CORP. PLC REG.SHS(SP.ADRS NEW)/1 LS-,50 (WK
https://finance.yahoo.com/news/...s-last-patient-study-090000988.html
Studienergebnisse im September
"This acceptance as a presentation of late-breaking clinical trial results is based on the ability of REDUCE-IT to address a critical question in cardiovascular prevention. The AHA has reviewed the design of the REDUCE-IT study, however, they have not yet seen the results of the study. As Amarin has guided in the past, topline results of this study are anticipated to be made public prior to the end of this month, September 2018. The AHA has not been provided any advanced access to the results of this study. "
https://investor.amarincorp.com/news-releases/...ed-presentation-2018
positive Studienergebnisse der REDUCE-IT Studie
https://endpts.com/...ou-can-bet-that-makes-some-people-very-unhappy/
https://finance.yahoo.com/m/...B%24%24%5D-surprise-heart-data-is.html
https://www.google.de/...3651730&usg=AOvVaw11BGHAjz-4vGnwtQzQqRZr
Read more at:
https://thefly.com/landingPageNews.php?id=2804759
Nov 10, 2018
Landmark Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular Outcomes Study of a Drug Intended to Address Residual Cardiovascular Risk Remaining After Cholesterol Management
Cardiovascular Death Reduced by 20%
Fatal or Nonfatal Heart Attacks Reduced by 31%
Fatal or Nonfatal Stroke Reduced by 28%
Urgent or Emergent Coronary RevascularizationReduced by 35%
Hospitalization for Unstable AnginaReduced by 32%
Number Needed to Treat for Primary Composite Endpoint: 21
Patient Years of Study Support Favorable Benefit/Risk Profile in REDUCE-IT
Affordably Priced Vascepa Positions Amarin with Potential to Help Millions of Patients
Conference Call Scheduled for Today, Saturday, November 10, 2018 at 7:15 pm CT/8:15 pm ET
Moderation
Zeitpunkt: 13.11.18 18:18
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - Unbelegte Aussage.
Zeitpunkt: 13.11.18 18:18
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - Unbelegte Aussage.
Erzähl kein Lügen, Amarins Vascepa wirkt beeindruckend, 25 % Reduktion und mehr bei CV-Todesfällen, Herzinfarkt, Schlaganfällen bei Zugabe zu Statinen,
... (automatisch gekürzt) ...
https://www.cnbc.com/2018/11/12/...stand-the-data-as-stock-drops.html
Moderation
Zeitpunkt: 13.11.18 11:27
Aktion: Kürzung des Beitrages
Kommentar: Urheberrechtsverletzung, ggf. Link-Einfügen nutzen
Original-Link: https://www.cnbc.com/2018/11/12/...data-as-stock-drops.html
Zeitpunkt: 13.11.18 11:27
Aktion: Kürzung des Beitrages
Kommentar: Urheberrechtsverletzung, ggf. Link-Einfügen nutzen
Original-Link: https://www.cnbc.com/2018/11/12/...data-as-stock-drops.html
"Thero defended the results, saying the mineral oil was reviewed and approved by the Food and Drug Administration prior to the study."